A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Financial Summary
| Share Statistics | ALPMY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $24,754.9 | $579.1 | 88% |
|
| Shares Out (Mil) | 11.3 | 43.0 | 22% |
|
| Institutional Ownership | 50.0% | 84.3% | 30% |
|
| Float (Mil) | 1,746.4 | 46.8 | 95% |
|
| Beta | 0.07 | 0.62 | 8% |
|
| Avg Daily Volume (000s) | 205 | 285 | 45% |
|
| Price Change (52-week) |
32.7% | 63.8% | 71% |
|
| Growth | ALPMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.6% | 6.7% | 29% |
|
| Net Income (5yr) | 11.0% | (1.4%) | 57% |
|
| EPS (5yr) | 11.7% | 14.9% | 50 |
|
| Dividends (5yr) | 5.3% | 0.0% | 69% |
|
| Cash Flow (5yr) | 65.7% | (14.9%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ALPMY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $13,454 | $272 | 87% |
|
| Net Income (TTM) (Mil) | $1,834 | ($11) | 92% |
|
| EPS (TTM) | $1.024 | ($0.500) | 61% |
|
| Operating Cash Flow (TTM) (Mil) | $3,523 | ($6) | 93% |
|
| Net Cash Flow (TTM) (Mil) | $643 | $4 | 93% |
|
| Long-Term Debt (Q1) (Mil) | $2,571 | $7 | 77% |
|
| Enterprise Value (Q1) (Mil) | $26,659 | $522 | 87% |
|
| Valuation | ALPMY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ALPMY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 80.9% | 65.9% | 90% |
|
| Net Margin | 13.6% | 0.7% | 71% |
|
| ROA | 8.0% | (24.6%) | 83% |
|
| ROE | 16.6% | (19.7%) | 74% |
|
| Liabilities to Assets | 48.7% | 35.5% | 40% |
|
| F-Score | na | 3 | na |
|
Astellas Pharma Inc. did not pass any screens on 7/31/2026.
